Regen BioPharma, Inc. filings document capital formation, share issuance activity, and material agreements tied to its HemaXellerate development program. Recent Form 8-K reports describe unregistered sales of common stock, Regulation A offering sales, conversions of principal and accrued interest on convertible debt, and changes in reported common shares outstanding.
The company’s filings also cover preferred-stock dividend actions and consulting or compensation agreements connected with a planned Phase I clinical trial of HemaXellerate. These regulatory records frame Regen BioPharma as a Nevada biopharmaceutical issuer with disclosures centered on equity financing, convertible indebtedness, clinical-development arrangements, governance actions, and capital structure.
Regen BioPharma, Inc. entered into two equity-based consulting arrangements tied to a planned Phase I clinical trial of its HemaXellerate therapy. The company granted twenty million newly issued common shares to consultant Dr. Harry Lander and twenty million newly issued common shares to Chairman and CEO David Koos, each subject to vesting upon successful completion of the trial. The shares were issued as unregistered securities under Section 4(a)(2) of the Securities Act without underwriters, commissions, or general solicitation. As of October 3, 2025, Regen BioPharma had 79,374,704 common shares outstanding.
Regen BioPharma, Inc. disclosed that it raised cash through several unregistered sales of common stock to unaffiliated investors in mid-September 2025. On September 15, 2025 the company issued 3,320,000 common shares for cash consideration of $33,200, on September 16, 2025 it issued 1,000,000 shares for $10,000, and on September 18, 2025 it issued 1,500,000 shares for $15,000.
The shares were issued in reliance on Regulation A exemptions from registration under the Securities Act of 1933. No underwriters were involved, the sales were conducted directly by management without commissions or other consideration paid, and the company states that proceeds from each sale will be used for working capital.